natgillin/translations-raw huggingface dataset:
However, tenofovir disoproxil reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses. 
Međutim, tenofovirdizoproksil smanjio je indeks vijabilnosti i tjelesnu težinu mladunčadi u ispitivanju perinatalne i postnatalne toksičnosti pri dozama koje su bile toksične za skotnu ženku.
Subjects whose virus expressed an L74V RT substitution without zidovudine resistance-associated substitutions (n = 8) had reduced response to tenofovir disoproxil. 
Ispitanici čiji je virus eksprimirao supstituciju L74V u reverznoj transkriptazi, bez supstitucija povezanih s rezistencijom na zidovudin (n=8), imali su smanjen odgovor na tenofovirdizoproksil.
• decreased number of red blood cells in your blood (anaemia) 
• smanjen broj crvenih krvnih stanica u krvi (anemija)
There are no or limited amount of data from the use of doravirine in pregnant women. 
Nema podataka ili su podaci o primjeni doravirina u trudnica ograničeni.
Tenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5´-triphosphate and, after incorporation into DNA, by DNA chain termination. 
Tenofovirdifosfat inhibira djelovanje reverzne transkriptaze HIV-1 kompeticijom s prirodnim supstratom deoksiadenozin 5´-trifosfatom te, nakon ugradnje u DNK, prekidanjem lanca DNK.
Laboratory strains of HIV-1 harbouring the common NNRTI-associated mutations K103N, Y181C, or K103N/Y181C substitutions in RT exhibit less than a 3-fold decrease in susceptibility to doravirine compared to wild-type virus when evaluated in the presence of 100 % normal human serum. 
Laboratorijski sojevi HIV-1 koji nose česte mutacije povezane s rezistencijom na NNRTI-je (K103N, Y181C) ili supstitucije K103N/Y181C u reverznoj transkriptazi pokazuju manje nego trostruko smanjenje osjetljivosti na doravirin u odnosu na virus divljeg tipa kada su se ispitivali u prisutnosti 100%-tnog normalnog humanog seruma.
Co-administration with the moderate CYP3A inducer rifabutin decreased doravirine concentrations (see Table 1). 
Istodobna primjena s umjerenim induktorom CYP3A rifabutinom snizila je koncentracije doravirina (vidjeti Tablicu 1).
Following oral administration of a single 245 mg dose of tenofovir disoproxil to HIV-1-infected subjects in the fasted state, Cmax was achieved in one hour. 
Nakon peroralne primjene jednokratne doze tenofovirdizoproksila od 245 mg natašte u ispitanika s HIV-1 infekcijom, Cmax je postignut za sat vremena.
The median EC50 values of lamivudine were 60 nM (range: 20 to 70 nM), 35 nM (range: 30 to 40 nM), 30 nM (range: 20 to 90 nM), 20 nM (range: 3 to 40 nM), 30 nM (range: 1 to 60 nM), 30 nM (range: 20 to 70 nM), 30 nM (range: 3 to 70 nM), and 30 nM (range: 20 to 90 nM) against HIV-1 clades A-G and group O viruses (n = 3 except n = 2 for clade B) respectively. 
Medijan vrijednosti EC50 za lamivudin iznosio je 60 nM (raspon: 20 - 70 nM), 35 nM (raspon: 30 - 40 nM), 30 nM (raspon: 20 - 90 nM), 20 nM (raspon: 3 - 40 nM), 30 nM (raspon: 1 - 60 nM), 30 nM (raspon: 20 - 70 nM), 30 nM (raspon: 3 - 70 nM) i 30 nM (raspon: 20 - 90 nM) protiv podtipova A - G virusa HIV-1 i virusa iz skupine O (n=3, osim n=2 za podtip B).
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs (see section 4.4). 
Neki primjeri uključuju, ali ne isključivo, aciklovir, cidofovir, ganciklovir, valaciklovir, valganciklovir, aminoglikozide (npr. gentamicin) i visoke doze ili više NSAIL-ova primijenjenih istovremeno (vidjeti dio 4.4).
Rare musculoskeletal pain, osteomalacia (manifested as bone pain and infrequently contributing to fractures)*, myopathy* 
rijetko bol u mišićima i kostima, osteomalacija (koja se manifestira kao bol u kostima i ponekad doprinosi prijelomima)*, miopatija*
• headache, dizziness, sleepiness 
• glavobolja, omaglica, pospanost
Exclusionary NNRTI substitutions were those listed above (DRIVE-FORWARD and DRIVE-AHEAD), with the exception of substitutions RT K103N, G190A and Y181C (accepted in DRIVE-SHIFT). 
Isključujuće supstitucije povezane s rezistencijom na NNRTI-je bile su one navedene gore (ispitivanja DRIVE-FORWARD i DRIVE-AHEAD), uz izuzetak supstitucija u reverznoj transkriptazi K103N, G190A i Y181C (prihvaćene u ispitivanju DRIVE-SHIFT).
• sofosbuvir/velpatasvir (medicines used to treat hepatitis C infection) 
• sofosbuvir/velpatasvir (lijekovi koji se koriste za liječenje infekcije virusom hepatitisa C)
Baseline regimen = ritonavir or cobicistat-boosted PI (specifically atazanavir, darunavir, or lopinavir), or cobicistat-boosted elvitegravir, or NNRTI (specifically efavirenz, nevirapine, or rilpivirine), each administered with two NRTIs. 
Početni režim = inhibitor proteaze pojačan ritonavirom ili kobicistatom (posebno atazanavir, darunavir ili lopinavir), ili elvitegravir pojačan kobicistatom, ili NNRTI (posebno efavirenz, nevirapin ili rilpivirin), svaki primijenjen s dva NRTI-ja.
The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines including monocytes and peripheral blood mononuclear cells (PBMCs) using standard susceptibility assays. 
Antivirusna aktivnost lamivudina protiv HIV-1 ocjenjivala se u nizu staničnih kultura, uključujući monocite i mononuklearne stanice iz periferne krvi, korištenjem standardnih testova osjetljivosti.
Cmax and AUC values were 0.30 ± 0.09 micrograms per mL and 2.29 ± 0.69 µg•hr per mL, respectively. 
Cmax je iznosio 0,30 ± 0,09 μg/ml, a AUC 2,29 ± 0,69 µg•h/ml.
The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in T lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes. 
Antivirusna aktivnost tenofovirdizoproksila protiv laboratorijskih i kliničkih izolata HIV-1 ocjenjivala se u T-limfoblastoidnim staničnim linijama, prvenstveno monocitima/makrofagima i limfocitima iz periferne krvi.
If you forget to take Delstrigo 
Ako ste zaboravili uzeti Delstrigo
Lamivudine and tenofovir disoproxil are primarily excreted by the kidney. 
Lamivudin i tenofovirdizoproksil primarno se izlučuju kroz bubrege.
Based on the lamivudine data, Delstrigo is not recommended for patients with CrCl of < 50 mL/min. 
S obzirom na podatke o lamivudinu, ne preporučuje se primjena lijeka Delstrigo u bolesnika kojima je CrCl < 50 ml/min.
Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. 
Ispitivanja reproduktivne toksičnosti u štakora i kunića nisu pokazala učinke na parenje, plodnost, skotnost ni fetalne parametre.
No significant cross-resistance has been demonstrated between doravirine-resistant HIV-1 variants and lamivudine/emtricitabine or tenofovir or between lamivudine- or tenofovir-resistant variants and doravirine. 
Nije utvrđena značajna križna rezistencija između varijanti HIV-1 rezistentnih na doravirin i lamivudina/emtricitabina ili tenofovira ni između varijanti rezistentnih na lamivudin ili tenofovir i doravirina.
• decreased number of white blood cells in your blood (neutropenia) 
• smanjen broj bijelih krvnih stanica u krvi (neutropenija)
Therefore, caution is advised when doravirine/lamivudine/tenofovir disoproxil is administered to patients with severe hepatic impairment (see section 5.2). 
Stoga se preporučuje oprez kada se doravirin/lamivudin/tenofovirdizoproksil primjenjuje u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 5.2).
Persistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in at risk patients. 
Bol u kostima koja perzistira ili se pogoršava, bol u ekstremitetima, prijelomi i/ili bol u mišićima ili slabost mišića mogu biti manifestacije proksimalne bubrežne tubulopatije i trebale bi potaknuti ocjenu funkcije bubrega u rizičnih bolesnika.
Tenofovir disoproxil requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. 
Tenofovirdizoproksilu je najprije potrebna hidroliza diestera da bi se pretvorio u tenofovir, a zatim fosforilacija djelovanjem staničnih enzima da bi nastao tenofovirdifosfat.
Subjects must have been virologically suppressed (HIV-1 RNA < 40 copies/mL) on their baseline regimen for at least 6 months prior to trial entry, with no history of virologic failure, and a documented absence of RT substitutions conferring resistance to doravirine, lamivudine and tenofovir (see section, Resistance). 
Virološka supresija (HIV-1 RNK < 40 kopija/ml) morala je biti postignuta početnim režimom u ispitanika tijekom najmanje 6 mjeseci prije ulaska u ispitivanje, pri čemu u anamnezi nije zabilježen izostanak virološkog odgovora, uz dokumentiranu odsutnost supstitucija u reverznoj transkriptazi koje donose rezistenciju na doravirin, lamivudin i tenofovir (vidjeti dio Rezistencija).
Each carton contains a high density polyethylene (HDPE) bottle with a polypropylene child-resistant closure with silica gel desiccants. 
Jedno pakiranje sadrži bocu od polietilena visoke gustoće (HDPE) zatvorenu polipropilenskim zatvaračem sigurnim za djecu koja sadrži silika-gel kao sredstvo za sušenje.
• thioridazine (a medicine to treat psychiatric conditions such as schizophrenia) 
• tioridazin (lijek za liječenje psihijatrijskih bolesti, kao što je shizofrenija)
In patients at risk of renal dysfunction, including patients who have previously experienced renal events while receiving adefovir dipivoxil, it is recommended that estimated CrCl, serum phosphorus, urine glucose, and urine protein be assessed prior to initiation of Delstrigo and more frequent renal function monitoring should be assessed as appropriate per the patient's medical condition during Delstrigo therapy. 
U bolesnika u kojih postoji rizik od poremećaja funkcije bubrega, uključujući bolesnike koji su prethodno imali bubrežne događaje tijekom liječenja adefovirdipivoksilom, preporučuje se prije uvođenja lijeka Delstrigo ocijeniti vrijednosti procijenjenog CrCl, vrijednosti fosfora u serumu, vrijednosti glukoze u mokraći i vrijednosti proteina u mokraći te po potrebi češće kontrolirati funkciju bubrega tijekom liječenja lijekom Delstrigo, u skladu s bolesnikovim medicinskim stanjem.
The pharmacokinetics of tenofovir following a 245 mg dose of tenofovir disoproxil have been studied in healthy subjects with moderate to severe hepatic impairment. 
Farmakokinetika tenofovira nakon doze tenofovirdizoproksila od 245 mg ispitivala se u zdravih ispitanika s umjerenim do teškim oštećenjem funkcije jetre.
• cough, nasal symptoms 
• kašalj, nosni simptomi
Findings in the rat and monkey studies indicated that there was a substance related decrease in intestinal absorption of phosphate with potential secondary reduction in BMD. 
Nalazi dobiveni u ispitivanjima na štakorima i majmunima ukazali su na smanjenje apsorpcije fosfata u crijevima povezano s primjenom djelatne tvari, uz potencijalno sekundarno smanjenje BMD-a.
Rare acute kidney injury, renal disorder, calculus urinary, nephrolithiasis, acute renal failure*, renal failure*, acute tubular necrosis*, nephritis (including acute interstitial)*, nephrogenic diabetes insipidus* 
rijetko akutna ozljeda bubrega, poremećaj bubrega, mokraćni kamenac, nefrolitijaza, akutno zatajenje bubrega*, zatajenje bubrega*, akutna tubularna nekroza*, nefritis (uključujući akutni intersticijski)*, nefrogeni dijabetes insipidus*
Single dose lamivudine oral solution 300 mg lamivudine 
Jednokratna doza oralne otopine lamivudina od 300 mg lamivudin
When possible, avoid chronic co-administration of doravirine/lamivudine/tenofovir disoproxil with medicinal products containing sorbitol or other osmotic acting polyalcohols (e.g., xylitol, mannitol, lactitol, maltitol). 
Kada je to moguće, potrebno je izbjegavati dugoročnu primjenu doravirina/lamivudina/ tenofovirdizoproksila s lijekovima koji sadrže sorbitol ili druge polialkohole s osmotskim djelovanjem (npr. ksilitol, manitol, laktitol, maltitol).
No dose adjustment of Delstrigo is required in adults with estimated creatinine clearance (CrCl) ≥ 50 mL/min. 
Nije potrebno prilagođavati dozu lijeka Delstrigo u odraslih osoba s procijenjenim klirensom kreatinina (CrCl) ≥ 50 ml/min.
• nafcillin (a medicine to treat some bacterial infections) 
• nafcilin (lijek za liječenje nekih bakterijskih infekcija)
Findings in repeat-dose toxicity studies in rats, dogs and monkeys at exposure levels greater than or equal to clinical exposure levels and with possible relevance to clinical use included kidney and bone changes and a decrease in serum phosphate concentration. 
Rezultati ispitivanja toksičnosti ponovljenih doza provedenih na štakorima, psima i majmunima pri razinama izloženosti većima ili jednakima kliničkim razinama izloženosti koji bi mogli biti značajni za kliničku primjenu uključivali su promjene na bubrezima i kostima te sniženje koncentracije fosfata u serumu.
Delstrigo is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir (see sections 4.4 and 5.1). 
Delstrigo je indiciran za liječenje odraslih osoba s infekcijom virusom humane imunodeficijencije tipa 1 (HIV-1) bez prethodnih ili trenutačnih dokaza rezistencije na lijekove iz skupine nenukleozidnih inhibitora reverzne transkriptaze (engl. non-nucleoside reverse transcriptase inhibitors, NNRTI), lamivudin ili tenofovir (vidjeti dijelove 4.4 i 5.1).
Oral carcinogenicity studies in rats and mice only revealed a low incidence of duodenal tumours at an extremely high-dose in mice. 
Ispitivanja kancerogenosti nakon peroralne primjene provedena na štakorima i miševima pokazala su samo nisku incidenciju tumora dvanaesnika pri ekstremno visokim dozama u miševa.
Compared with subjects with normal renal function, the mean (% CV) tenofovir exposure increased from 2,185 (12 %) ng·h/mL in subjects with CrCl > 80 mL/min to respectively 3,064 (30 %) ng·h/mL, 6,009 (42 %) ng·h/mL and 15,985 (45 %) ng·h/mL in subjects with mild, moderate, and severe renal impairment. 
U usporedbi s ispitanicima s normalnom funkcijom bubrega, srednja vrijednost (% CV) izloženosti tenofoviru porasla je s 2185 (12%) ng·h/ml u ispitanika kojima je CrCl iznosio > 80 ml/min na 3064 (30%) ng·h/ml, 6009 (42%) ng·h/ml i 15 985 (45%) ng·h/ml u ispitanika s blagim, umjerenim odnosno teškim oštećenjem funkcije bubrega.
Discontinued study due to AE or Death 
Prekid ispitivanja zbog štetnog događaja ili smrti
GM: Geometric mean, %CV: Geometric coefficient of variation 
Geometric coefficient of variation): geometrijski koeficijent varijacije
Co-administration of doravirine/lamivudine/tenofovir disproxil and medicinal products that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. 
Istodobna primjena doravirina/lamivudina/tenofovirdizoproksila i lijekova koji su inhibitori CYP3A može povisiti koncentracije doravirina u plazmi.
In the DRIVE-SHIFT trial, an immediate switch to Delstrigo was demonstrated to be non-inferior at Week 48 compared to continuation of the baseline regimen at Week 24 as assessed by the proportion of subjects with HIV-1 RNA < 40 copies/mL. 
U ispitivanju DRIVE-SHIFT, prelazak na Delstrigo bez odgode pokazao se neinferiornim u 48. tjednu u usporedbi s nastavkom početnog režima u 24. tjednu, što je procijenjeno prema omjeru ispitanika s HIV-1 RNK < 40 kopija/ml.
Doravirine is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A are expected to affect the clearance of doravirine (see section 5.2). 
Budući da se doravirin primarno metabolizira putem CYP3A, očekuje se da će lijekovi koji induciraju ili inhibiraju CYP3A utjecati na klirens doravirina (vidjeti dio 5.2).
• feeling weak, general feeling of being unwell 
• slabost, opće loše osjećanje
Other substitutions yielded a fold change of 5-10 (G190S (5.7); K103N/P225H (7.9), V108I/Y181C (6.9), Y181V (5.1)). 
Uz ostale supstitucije zabilježena je promjena 5 - 10 puta (G190S [5,7 puta], K103N/P225H [7,9 puta], V108I/Y181C [6,9 puta], Y181V [5,1 put]).
Lamivudine was mutagenic in an L5178Y mouse lymphoma assay and clastogenic in a cytogenetic assay using cultured human lymphocytes. 
Lamivudin je bio mutagen u testu na stanicama mišjeg limfoma L5178Y i klastogen u citogenetskom testu na kulturi humanih limfocita.
The clinically relevant effects noted were a reduction in red blood cell count and neutropenia. 
Opaženi klinički značajni učinci bili su smanjenje broja eritrocita i neutropenija.
• ledipasvir/sofosbuvir (medicines used to treat hepatitis C infection) 
• ledipasvir/sofosbuvir (lijekovi koji se koriste za liječenje infekcije virusom hepatitisa C)
Metabolism and nutrition disorders Uncommon hypophosphataemia, hypokalaemia* 
Poremećaji metabolizma i prehrane manje često hipofosfatemija, hipokalijemija*
• feeling of incomplete defecation 
• osjećaj nepotpunog pražnjenja crijeva
Because a negligible amount of lamivudine was removed via (4-hour) haemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous haemodialysis would provide clinical benefit in a lamivudine overdose event. 
Budući da je (4-satnom) hemodijalizom, kontinuiranom ambulantnom peritonejskom dijalizom i automatiziranom peritonejskom dijalizom uklonjena zanemariva količina lamivudina, nije poznato bi li kontinuirana hemodijaliza bila klinički korisna u slučaju predoziranja lamivudinom.
Tenofovir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC50 values ranged from 0.5-2.2 microM). 
Tenofovir je u staničnoj kulturi pokazao antivirusnu aktivnost protiv virusa HIV-1 podtipa A, B, C, D, E, F, G i O (vrijednosti EC50 kretale su se u rasponu od 0,5 do 2,2 µM).
Pharmacokinetic parameters of tenofovir were determined following administration of a single dose of tenofovir disoproxil 245 mg to 40 non-HIV infected adult subjects with varying degrees of renal impairment defined according to baseline CrCl (normal renal function when CrCl > 80 mL/min; mild with CrCl = 50-79 mL/min; moderate with CrCl = 30-49 mL/min and severe with CrCl = 10-29 mL/min). 
Farmakokinetički parametri tenofovira određivali su se nakon primjene jednokratne doze tenofovirdizoproksila od 245 mg u 40 odraslih ispitanika bez HIV infekcije koji su imali različite stupnjeve oštećenja funkcije bubrega definiranog prema početnom klirensu kreatinina (normalna funkcija bubrega: CrCl > 80 ml/min; blago oštećenje: CrCl=50 - 79 ml/min; umjereno oštećenje: CrCl=30 - 49 ml/min; teško oštećenje: CrCl=10 - 29 ml/min).
• 1 bottle with 30 film-coated tablets 
• 1 boca s 30 filmom obloženih tableta
DOR + NRTIs* 
DOR + NRTI-ji*
Subsequently F227(L/C/V) or L234I emerged in addition to V106 substitutions (double mutants yielding a fold change of > 100). 
Nakon toga se uz supstitucije V106 javila i mutacija F227(L/C/V) ili L234I (dvostruke mutacije koje su dovele do promjene > 100 puta u odnosu na početnu vrijednost).
• feeling sick (nausea), diarrhoea, stomach pain, vomiting, wind (flatulence) 
• mučnina, proljev, bol u trbuhu, povraćanje, vjetrovi (flatulencija)
Bone problems include bone pain, and bone softening or thinning (which may lead to fractures). 
Tegobe s kostima uključuju bol u kostima te omekšavanje ili stanjivanje kosti (koje može dovesti do prijeloma).
• This medicinal product does not require any special temperature storage conditions. 
• Lijek ne zahtijeva čuvanje na određenoj temperaturi.
• St. John's wort (Hypericum perforatum) 
• gospinu travu (Hypericum perforatum)
Doravirine was not genotoxic in a battery of in vitro or in vivo assays. 
Doravirin Doravirin nije bio genotoksičan u nizu testova in vitro ili in vivo.
Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of Delstrigo (see sections 4.4 and 4.5). 
Istodobna primjena s lijekovima koji su snažni induktori enzima citokroma P450 CYP3A kontraindicirana je jer se očekuju značajna sniženja koncentracija doravirina u plazmi, koja mogu smanjiti učinkovitost lijeka Delstrigo (vidjeti dijelove 4.4 i 4.5).
If a patient misses a dose of Delstrigo by more than 12 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. 
Ako je od propuštene doze prošlo više od 12 sati, bolesnik ne smije uzeti propuštenu dozu, nego treba uzeti sljedeću predviđenu dozu prema uobičajenom rasporedu.
Delstrigo is a complete regimen taken as a single tablet for the treatment of HIV infection. 
Delstrigo je cjelovit režim za liječenje HIV infekcije, koji se uzima u obliku jedne tablete.
Doravirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes, as well as NNRTI-resistant HIV-1. 
Sojevi rezistentni na doravirin izdvojeni su u staničnoj kulturi, počevši od HIV-1 divljeg tipa različitog podrijetla i podtipova te HIV-1 rezistentnog na NNRTI-je.
In DRIVE-FORWARD, 766 subjects were randomised and received at least 1 dose of either doravirine 100 mg or darunavir + ritonavir 800+100 mg once daily, each in combination with emtricitabine/tenofovir disoproxil (FTC/TDF) or abacavir/lamivudine (ABC/3TC) selected by the investigator. 
U ispitivanju DRIVE-FORWARD, randomizirano je 766 ispitanika koji su primili najmanje 1 dozu doravirina od 100 mg jedanput na dan ili darunavira + ritonavira u dozi od 800+100 mg jedanput na dan, svaki u kombinaciji s emtricitabinom/tenofovirdizoproksilom (FTC/TDF) ili abakavirom/lamivudinom (ABC/3TC), prema izboru ispitivača.
Tenofovir Cmax decreased by 12 % and AUC increased by 27 % with a high fat meal. 
Cmax tenofovira se uz obrok s visokim udjelom masnoća smanjio za 12%, dok se AUC povećao za 27%.
HIV-1 isolates with the K65R substitution also showed reduced susceptibility to emtricitabine and lamivudine. 
Izolati HIV-1 sa supstitucijom K65R pokazali su i smanjenu osjetljivost na emtricitabin te lamivudin.
• sirolimus (a medicine used to control your body's immune response after a transplant) 
• sirolimus (lijek koji se koristi za kontroliranje odgovora imunološkog sustava nakon presađivanja)
Film-coated tablets 30 film-coated tablets 90 (3 bottles of 30) film-coated tablets 
Filmom obložene tablete 30 filmom obloženih tableta 90 (3 boce s 30) filmom obloženih tableta
How Delstrigo works 
Kako Delstrigo djeluje
• joint pain, breakdown of muscle tissue, muscular weakness 
• bol u zglobovima, oštećenje mišićnog tkiva, slabost u mišićima
At baseline, the median age of subjects was 31 years (range 18-70 years), 85 % were male, 52 % were non-white, 3 % had hepatitis B or C co-infection, 14 % had a history of AIDS, 21 % had HIV-1 RNA > 100,000 copies per mL, and 12 % had CD4 
Medijan dobi ispitanika na početku ispitivanja iznosio je 31 godinu (raspon: 18 - 70 godina), 85% bili su muškarci, 52% ispitanika nije bilo bijele rase, 3% istodobno je imalo infekciju virusom hepatitisa B ili C, 14% imalo je AIDS u anamnezi, 21% imalo je razinu HIV-1 RNK višu od 100 000 kopija/ml, a 12% ih je imalo broj CD4
Expected: ↑ tenofovir 
Očekivano: ↑ tenofovir
The oral bioavailability of tenofovir from tenofovir disoproxil in fasted subjects is approximately 25 %. 
Bioraspoloživost tenofovira iz tenofovirdizoproksila nakon peroralne primjene iznosi približno 25%.
*This adverse reaction was not identified as an adverse reaction associated with doravirine from the Phase 3 clinical studies (DRIVE-FORWARD, DRIVE-AHEAD, DRIVE-SHIFT), but is included in this table as an adverse reaction based on the Summary of Product Characteristics of 3TC and/or TDF. 
*Ova nuspojava nije utvrđena kao nuspojava povezana s doravirinom u kliničkim ispitivanjima faze 3 (DRIVE-FORWARD, DRIVE-AHEAD, DRIVE-SHIFT), ali je kao nuspojava uključena u ovu tablicu prema sažetku opisa svojstava lijeka za lamivudin (3TC) i/ili tenofovirdizoproksilfumarat (TDF).